1. Home
  2. JVA vs XCUR Comparison

JVA vs XCUR Comparison

Compare JVA & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

JVA

Coffee Holding Co. Inc.

HOLD

Current Price

$4.29

Market Cap

17.8M

ML Signal

HOLD

XCUR

Exicure Inc.

HOLD

Current Price

$2.89

Market Cap

17.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JVA
XCUR
Founded
1971
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.8M
17.6M
IPO Year
1997
2017

Fundamental Metrics

Financial Performance
Metric
JVA
XCUR
Price
$4.29
$2.89
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
34.1K
12.3K
Earning Date
06-12-2026
03-25-2026
Dividend Yield
1.71%
N/A
EPS Growth
N/A
83.37
EPS
0.29
N/A
Revenue
$90,655,294.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$14.48
N/A
Revenue Growth
17.54
N/A
52 Week Low
$2.93
$2.62
52 Week High
$5.62
$9.50

Technical Indicators

Market Signals
Indicator
JVA
XCUR
Relative Strength Index (RSI) 45.06 40.57
Support Level $4.08 $2.62
Resistance Level $4.75 $3.50
Average True Range (ATR) 0.19 0.25
MACD -0.02 0.01
Stochastic Oscillator 20.24 21.08

Price Performance

Historical Comparison
JVA
XCUR

About JVA Coffee Holding Co. Inc.

Coffee Holding Co Inc is engaged in wholesale coffee operations, including manufacturing, roasting, packaging, marketing, and distributing roasted and blended coffees for privately labeled accounts and its brands, and it sells green coffee. The Company also manufactures and sells coffee roasters. Its products include wholesale green coffee, private-label coffee, and branded coffee. The company sells its coffee products throughout the United States, Canada, and certain Asian countries. The group's services are Custom Blending, Food Service Programs, and Private Label Services.

About XCUR Exicure Inc.

Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.

Share on Social Networks: